Inclusion Criteria:

          1. Patients must be 18 years to 70 years;

          2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer;

          3. Patients must have a KPS of >80, expected survival > 3 months;

          4. Patients must have at least one measurable lesions;

          5. Recently did not use glucocorticoid;

          6. Patients must have evidence of adequate hepatic and renal function as evidenced by the
             following laboratory parameters: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST
             ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN，

          7. Patients must have a good heart function (LVEF>50%) ;

          8. Patients must be willing to practice birth control during and for three months
             following treatment.NOTE:female participants of reproductive potential must have a
             negative serum pregnancy test, and willing to practice birth control during and for
             three months following treatment；

          9. Patients must be willing to sign an informed consent.

        Exclusion Criteria:

          1. Patients with other cancer history;

          2. Patients allergic to cetuximab;

          3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia;

          4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ;

          5. Patients with acute and chronic GVHD (graft versus host disease)

          6. Patients with severe autoimmune diseases;

          7. Previously treatment with T cell inhibitors (cyclophosphamide, FK506);

          8. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis
             serology reaction positive;

          9. Patients who are participating or participated any other clinical research in the past
             1 months;

         10. Pregnant and/or lactating women will be excluded; -